The kid e is o e of the od 's ai filtratio orga s, a d hence, opportunity exists for designing nanomedicine that can naturally accumulate in the kidneys for renal diseases. In addition to traditional physiochemical properties for kidney accumulation, such as size and charge, synthesized nanoparticles can be conjugated with targeting ligands which further home the nanocarrier to cell types of interest. In this review, we highlight key studies that have shown success in utilizing peptide-or antibody-based ligands in nanoparticles to target the glomerulus, podocytes, or renal tubule cells in the kidney. In addition, other ligand candidates which have shown renal affinity, but have not yet been integrated into a nanoparticle are also presented.
Introduction
Medications that are administered systemically have potential for adverse side effects. The kidney and liver are especially susceptible, as together they receive approximately 45% of the cardiac output, and are the main organs involved in excretion and metabolism of wastes in the body.
1,2
For instance, common antibiotics or non-steroidal, anti-inflammatory drugs may cause tubulointerstitial nephritis and acute tubular necrosis in the kidney when high doses are administered systemically. 3 Therefore, nanomedicine aims to exploit properties of matter at the nano scale to improve traditional therapeutics or create new opportunities for treatment. 4 For example, utilizing nanoparticles to encapsulate or conjugate therapeutics can improve pharmacokinetics, increase potency to a specific tissue type, or deliver molecules to tissues which are or all o sidered u drugga le due to the od 's immune and excretory systems. 5 In this review, we discuss key studies in nanomedicine towards kidney applications. We specifically focus on peptide-and antibody-based targeting ligands that have been used in nanoparticle studies. We also compile additional peptide and antibody ligands that show renal specificity, which may be used in nanoparticle systems in future efforts. Amino acid-based ligands are selected due to their biocompatibility and relatively safe degradation products. 6, 7 For an overview of kidney targeting strategies encompassing antibody mimetics, proteins, nucleic acids, and small-molecule ligands, refer to the review by Kamaly et al. 8 Here, we first summarize fundamental physical properties of nanoparticle size and charge that affect biodistribution, which pro ide a passi e targeti g effect toward the kidneys without specific ligand interaction with cells. Subsequently, targeting ligands reviewed will be categorized by the specific kidney cell type they target, which include the glomerular endothelial and epithelial cells, tubule cells, podocytes, or mesangium cells. This intra-kidney specificity is desirable to focus therapeutics specifically to diseased cell types, and minimize off target toxicity.
Renal Anatomy and Common Pathologies
The main repeating functional unit of the kidney is the nephron. Nephrons are organized into layers within the kidney, where the glomerulus, proximal and distal tubules residing mostly in the cortex, and the Loop of Henle and collecting duct form deeper layers in the medulla (Figure   1 ). 9 The first renal structure unfiltered blood encounters is the glomerulus. The glomerulus is comprised of a luster of apillaries surrou ded the Bo a 's apsule, which together form the renal corpuscle. This structure is lined with parietal epithelial cells, thought to serve as a reservoir for renal progenitor cells. 10 The interstitial spaces within the glomerular capillaries are occupied with mesangial cells, which provide the maintenance of capillary organization and support filtration processes for glomerular endothelial cells.
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The glomerular filtration barrier surrounds the endothelial cells and mesangial cells, which consists of the glomerular basement membrane as well as associated podocytes. The podocytes form interdigitating foot processes along the glomerular basement membrane, creating 4-11 nm slits that prevent the passage of large macromolecules. In sum, the kidney is an organ with many cell types exposed to ever changing external fluid compositions and concentrations. Acute kidney injury (AKI) is a broad term and historically assessed by the magnitude of serum creatinine concentration increase, a waste product generated by the muscles.
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Normal levels for a healthy individual range between 0.6-1.2 milligram per deciliter of blood. 13 Common causes of acute pathologies include hypotension/sepsis, trauma, acute tubular necrosis, contrast injury, and urinary obstruction.
14 Genetic predispositions may instead cause chronic conditions such as polycystic kidney disease or lupus nephritis. Repeated exposure to harmful substances and secondary chronic conditions such as diabetes or high blood pressure can also lead to glomerulonephritis. For a review of nanoparticles used for kidney applications categorized by disease type, refer to the review by Brede et al. 
Nanoparticle Size and Charge
Most studies have administered nanoparticles intravenously, as this delivery route offers the highest bioavailability. 16 One of the most studied factors in nanoparticle design is size, as differing diameters of the same nanoparticle composition can cause vastly different biodistribution profiles after injection. 17 In healthy kidneys, nanoparticles with hydrodynamic diameters up to 7
nm are able to pass through the glomerular membrane barriers and are cleared via renal excretion. 18, 19 The vast majority of studies indicate both rigid metal 20 or flexible polymer 21 nanoparticles in this size range are cleared by the kidney (Figure 2) . 22, 23 In diseased states, breakdown of the glomerular endothelial cell lining and podocyte architecture can lead to passage of much larger substances, leading to proteinuria. They were observed to localize in the basolateral region of proximal tubule epithelial cells under histological analysis. However, studies on the opposite end of the size spectrum, with ultrasmall nanoparticles <5.5 nm, indicate that charge is a primary determinant of kidney uptake or excretion. Negatively-charged quantum dots (QDs) (∼3.7 nm)
as a model system were used by Liang et al. and found to accumulate in mesangial cells, with little found in urine. 27 In contrast, cationic QDs of similar size (∼5.67 nm) were found to be readily excreted into urine shortly after injection. In addition, deviations from the general size trend can be achieved using glutathione, a naturally occurring tri-amino acid peptide present in both oxidized and reduced forms in human kidneys, when coated on copper nanoparticles of 2 nm average diameter. Yang et al. expected that dissociated components of this particle would be cleared by the kidney faster, as is the case with most nanoparticles that dissociate. 28, 29 However, these glutathione copper nanoparticles were found to clear faster compared to their dissociated components. This surprising result indicates that the surface modification can also dictate particle clearance. The authors discuss that the coated nanoparticles may have a lower affinity to serum protein adsorption compared to their fragments, allowing faster urinary system excretion.
Recently, density of the nanoparticle has also been shown to affect biodistribution. By again utilizing glutathione as a coating for gold or silver core nanoparticles of varying densities, Tang et al. found that renal clearance efficiency exponentially increased with a decrease in particle density two hours post-injection. 30 This behavior likely originates from density-dependent margination effect in blood circulation, where higher density nanoparticles circulate more slowly, thus leading to slower renal clearance.
Peptide Ligands
Active targeting of nanoparticles typically involve ligands bound to the surface which enables a higher degree of specificity compared to untargeted particles of the same physical characteristics such as size and charge. 31 Peptide ligands take advantage of highly specific interactions between the ligand and the target site to promote accumulation of nanoparticles.
Peptides are naturally degradable, easily synthesized, and custom tunable with a variety of linker chemistries. By employing targeting peptides to nanoparticles, drugs have the potential to reduce side effects and toxicity associated with current therapies for kidney disease, and can generate a higher intrarenal drug concentration compared to that of free drug. Table 1 is a summary of these targeting peptides. 
Podocytes
Podocytes surround the capillaries and mesangium, and possesses unique foot-like structures which aid in selectively filtering blood components. Many common genetic diseases affect podocytes such as Alport syndrome, membranous nephropathy, and segmental glomerular sclerosis. Secondary conditions such as hypertension and diabetic neuropathy can also cause podocyte dysfunction which results in kidney disease. 34 Pollinger et. al. developed cyclo(RGDfC)-modified quantum dots (Qdots), which are rod-shaped constructs with a length of 10 nm to 15 nm and a width of 5 nm. 35 Cyclo(RGDfC) was hypothesized to demonstrate ligand-specific binding for the α β integrin expressed on podocytes. This particular integrin is discussed to play a role in kidney viral infection, making it a candidate for facilitating cellular uptake. 36 Highly specific, cell and receptor binding was observed in an ex vivo study of primary podocytes. Confocal microscopy showed cellular Qdot uptake into vesicle-like structures within glomerular podocytes. The receptor mediated nature of nanoparticle binding to podocytes was further confirmed with a competition assay using free peptides.
Glomerular Endothelial Cell Barrier and Basement Membrane
The glomerular endothelial cells are adjacent to the glomerular capillaries, and form 60-80 nm intercellular pores, integral to the function of filtration. 8 Impairment of this endothelial surface layer leads to albuminuria and glomerulosclerosis. 37 The glomerular endothelial cells and podocytes secrete a layer of extracellular matrix which forms the glomerular basement membrane, composed of collagen IV, laminin, and proteoglycans. Closer examination via immunohistochemistry revealed that CLPVASC was found in both the glomeruli and between tubules of the kidney.
Tubular Cells
Tubular epithelial cells in the proximal tubule gather the urine to the collecting ducts, and exchange substances throughout the length of the tubule. This epithelium is highly susceptible to injury, and will be an important cellular target for therapies intended to treat proinflammatory and fibrogenic tubular injury. 42 Bidwell et al. modified the sequence suggested by Pasqualini et al., CLPVASC, with an elastin-like polypeptide (ELPs), to specifically target the tubule. 43 The authors discuss that fusing small-molecules and peptide therapeutics to relatively large, nonimmunogenic protein-based carrier ELPs can increase their stability for enhanced renal accumulation. This modified ELP peptide was hypothesized to behave like an extended rod-like protein, suggesting that it is filtered by the glomerulus and reaches the tubules by protein reuptake. One mechanism suggested to underlie this phenomenon is the hydrostatic forces orienting these rod-like structures perpendicularly to the basement membrane, enabling the insertion of their <10 nm axis through the membrane. demonstrated renal clearance within a few hours to prevent toxicity due to long kidney retention. 
Antibody Ligands
Antibodies are typically 200-300 nm in size proteins and are part of the adaptive immune system. Much like peptide-conjugated nanoparticles, antibody-conjugated nanoparticles can generate a product that delivers potent therapeutic or imaging agents that is highly specific to a certain tissue or antigen.
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We present antibody-nanoparticle systems that show renal accumulation to distinct cell types ( Table 2) . 
Glomerular Endothelial Cells and Basement Membrane
An antibody-conjugated nanoparticle strategy was used by Hultman to target the rat major histocompatibility class II (RT1 anti-MHC II). Vascular cell adhesion molecule-1 (VCAM-1), is an important regulatory molecule for leukocyte adhesion to tissues, and is upregulated in the kidney ischemia reperfusion injury.
Studies in animal models indicate that such ischemia activates endothelial cells, which upregulates the expression of VCAM-1. 55 Anti-VCAM 1 antibody conjugated to iron oxide microparticles 1 µm in diameter have been explored as a diagnostic tool for renal endothelial cell inflammation. 56 Anti-VCAM-1-conjugated particles were found to bind to the endothelium rapidly, occurring within minutes, which has potential as a fast-acting delivery vehicle for therapeutic or imaging agents. MRI contrast utilizing the iron composition of the microparticles was observed within 30 minutes of injection into mice, and persisted for the entire 90-minute imaging session. Accumulation of microparticles was evident in the renal cortex and medulla, and did not show any signs of local infarction or hemorrhage, confirming the potential of anti-VCAM-1-conjugated iron oxide as a diagnostic tool for renal inflammation.
Asgeirsdottir et al. focused on another inflammatory marker exploited for kidney targeting properties. 57, 58 Site-selective delivery of E-selectin targeting liposomes (AbEsel) on the order of 114 nm were shown to deliver encapsulated dexamethasone which reduces endothelial cell activation and counteracts glomerulonephritis progression. In an induced accelerated glomerulonephritis (GN) model generated from C57bl/6 mice, liposomes reduced glomerular proinflammatory gene expression but did not affect blood glucose levels, which is typically elevated to severe levels upon administration of free dexamethasone, demonstrating a classic benefit of nanoparticle drug delivery. Dexa-AbEsel liposomes reduced renal injury as shown by a reduction of blood urea nitrogen levels, decreased glomerular crescent formation, and downregulation of disease-associated genes in C57bl/6 mice. Immunohistochemistry confirmed uptake corresponded to the glomerular surface.
Liposomes were formulated and conjugated with an anti-α8 integrin antibody by Scindia et al., which allows for specific accumulation and targeting to mesangial cells. Renal inflammation imaging was successfully achieved by intravenous injection of SiNP with fluorescent-labeled anti-CD11b. After antibodies were immobilized on the SiNP surface such that specificity to the Fc region was preserved, nanoparticles were found to have a high affinity for macrophages at the site of renal damage.
Significantly higher affinity was observed for the orientation specific antibody SiNP compared with the antibody immobilized in a random orientation, or free antibody, indicating the importance of antibody orientation with respect to the particle for targeting.
Liposomes with antibodies against human renal cancer markers have also been investigated. 65 Dal K29, a murine IgGl monoclonal antibody against human renal cell carcinoma, was conjugated to unilamellar liposomes on the order of 600 to 800 nm in diameter to deliver methotrexate, a common chemotherapy and immunosuppressant. In vitro studies took place on the Caki-1 cell line, which is a human clear cell renal cell carcinoma that expresses characteristic features of the proximal tubule epithelium. Endocytosis of Dal K29-linked liposomes were observed, with some antibody-conjugated liposomes found in clathrin coated pits. 66 The liposome constructs were endocytosed more effectively and provided more potent inhibition of cancer cell growth compared to equimolar amounts of free methotrexate, as well as liposomes conjugated to nonspecific antibodies. This study demonstrates that nanoparticle conjugation with a targeting ligand has the potential to increase specificity as well as potency compared to systemic free drug administration.
In a mouse model of rhabdomyolysis-induced AKI, which releases myoglobin into the bloodstream to cause kidney damage, Rubio-Navarro et al. incorporated the antibody targeting the injury marker CD163, which is associated with apoptosis of proximal tubule cells. 67 Renal dysfunction was induced in mice through glycerol administration, which increased CD163 expression. Rhabdomyolysis-induced kidney injury in humans was also found to have enhanced CD163 expression compared to healthy tissues. Gold-coated iron oxide particles on the order of 6 nm were conjugated to anti-CD163 IgG antibodies, and electron microscopy confirmed the presence of these nanoparticles within interstitial macrophages in the kidney tubules in vivo. 68 Such molecular specificity to disease cell and tissue types can lead to early detection, along with more efficient therapeutic delivery. 
Conclusion

